Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Shares Outstanding for 12 consecutive years, with $88.5 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 2.9% year-over-year to $88.5 million; the TTM value through Mar 2026 reached $88.5 million, up 2.9%, while the annual FY2025 figure was $87.4 million, 2.0% up from the prior year.
  • Shares Outstanding hit $88.5 million in Q1 2026 for Syndax Pharmaceuticals, up from $87.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $88.5 million in Q1 2026 and bottomed at $55.0 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $76.9 million, with a median of $85.0 million recorded in 2024.
  • Year-over-year, Shares Outstanding rose 24.54% in 2023 and then increased 1.02% in 2024.
  • Syndax Pharmaceuticals' Shares Outstanding stood at $68.1 million in 2022, then rose by 24.54% to $84.8 million in 2023, then grew by 1.02% to $85.7 million in 2024, then grew by 2.0% to $87.4 million in 2025, then rose by 1.3% to $88.5 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $88.5 million, $87.4 million, and $86.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.